Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: A double blind, placebo-controlled cross over trial was conducted on 15 adult persistent rhinitis sufferers (diagnosed positive to Der p1 and/or Der f1 by SPT) and who had symptoms over the previous 2 years. The placebo was lactose powder. Challenge was by measured dose of homogenised allergenic dust. The study took place in the spring of 2006 before the main pollen seasons. MAIN OUTCOME MEASURES: The primary outcome measures were observed severity scores for 3 symptom categories and the amount of ECP in nasal secretions. The secondary outcome measures were symptom scores by subject report ( nasal blockage, itching of nose, throat and eyes), nasal peak inspiratory (PIFn) and expiratory flow (PEFn). RESULTS: The results show significant differences for sneezing, itchy nose, runny nose and ECPs in nasal secretions. Some results are also significantly different between placebo and active for PIFn and for PEFn (all at p = 0.05). There were no adverse reactions. CONCLUSIONS:
|
Authors | J C Emberlin, R A Lewis |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 23
Issue 10
Pg. 2423-31
(Oct 2007)
ISSN: 1473-4877 [Electronic] England |
PMID | 17767803
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Dermatophagoides
- Arthropod Proteins
- Placebos
- Powders
- Cellulose
- Cysteine Endopeptidases
- Dermatophagoides farinae antigen f 1
- Dermatophagoides pteronyssinus antigen p 1
|
Topics |
- Administration, Intranasal
- Adult
- Antigens, Dermatophagoides
(administration & dosage)
- Arthropod Proteins
- Cellulose
(administration & dosage)
- Cross-Over Studies
- Cysteine Endopeptidases
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Placebos
- Powders
- Rhinitis, Allergic, Perennial
(drug therapy)
|